Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
In Brief Posted: 12:31 PM PDT · September 23, 2026 Image Credits:Viswa Colluru / Enveda Marina Temkin Enveda secures $311M to bring more nature-derived AI drugs into clinical trials Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E…
In Brief Posted: 12:31 PM PDT · September 23, 2026 Image Credits:Viswa Colluru / Enveda Marina Temkin Enveda secures $311M to bring more nature-derived AI drugs into clinical trials Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation. The fresh funding, which was led by Catalio Capital Management, with participation from Iconiq and others, doubles the valuation Enveda achieved 12 months ago. The idea behind Enveda is that powerful medicines could be harnessed from plants and microbes, rather than synthesized from scratch in a lab. Viswa Colluru, an early employee of Recursion Pharmaceuticals, founded Enveda in 2019 to speed up the process of discovering these new drugs using AI and other techniques. While AI hasn’t yet produced any FDA-approved drugs, Enveda is among the wave of companies advancing AI-discovered candidates into human clinical trials. The startup is currently testing several drugs in patients, including one targeting severe skin conditions and another designed to help maintain weight loss after stopping GLP-1s. Topics AI, Biotech & Health, clinical trials, Enveda, In Brief, Startups October 13 – 15 San Francisco Your next big connection is at Disrupt.Connect with 10,000+ founders, VCs, operators, and tech leaders. Explore tomorrow’s breakthroughs, hear what’s shaping tech today, and save up to $200 by Sept. 25 at 11:59 p.m. PT. BOOK NOW Newsletters See More Subscribe for the industry’s biggest tech news Related TechCrunch Disrupt 2026 StrictlyVC at TechCrunch Disrupt 2026: Inside the changing rules of venture capital TechCrunch Events 14 hours ago Startups Snorkel AI triples valuation to $3.5B as demand for AI training data booms Marina Temkin 1 day ago AI Nscale’s IPO will test Wall Street’s appetite for concentrated AI bets once again Marina Temkin 2 days ago Latest in Biotech & Health AI Anthropic says its biology lab has already found something big Julie Bort 6 hours ago In Brief Enveda secures $311M to bring more nature-derived AI drugs into clinical trials Marina Temkin 9 hours ago TechCrunch Disrupt 2026 3 days left to save up to $200 and make impactful connections at TechCrunch Disrupt 2026 TechCrunch Events 15 hours agoSource: TechCrunch — Published — Category: Business